within Pharmacolibrary.Drugs.ATC.N;

model N06DA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 3.5000000000000004e-05,
    adminDuration  = 600,
    adminMass      = 3 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0018,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.024,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06DA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Rivastigmine is a reversible cholinesterase inhibitor approved for the symptomatic treatment of mild to moderate dementia related to Alzheimer’s and Parkinson’s diseases. It enhances cholinergic function by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following single oral dose administration.</p><h4>References</h4><ol><li><p>Agrawal, M, et al., &amp; Alexander, A (2018). Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 281 139–177. DOI:<a href=\"https://doi.org/10.1016/j.jconrel.2018.05.011\">10.1016/j.jconrel.2018.05.011</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29772289/\">https://pubmed.ncbi.nlm.nih.gov/29772289</a></p></li><li><p>Salimi, A, et al., &amp; Sharif Makhmalzadeh, B (2021). Dermal pharmacokinetics of rivastigmine-loaded liposomes: an . <i>Journal of liposome research</i> 31(3) 246–254. DOI:<a href=\"https://doi.org/10.1080/08982104.2020.1787440\">10.1080/08982104.2020.1787440</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32594811/\">https://pubmed.ncbi.nlm.nih.gov/32594811</a></p></li><li><p>Lefèvre, G, et al., &amp; Appel-Dingemanse, S (2008). Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects. <i>Journal of clinical pharmacology</i> 48(2) 246–252. DOI:<a href=\"https://doi.org/10.1177/0091270007312154\">10.1177/0091270007312154</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18199897/\">https://pubmed.ncbi.nlm.nih.gov/18199897</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06DA03;
